All In Biotech

Drug Trial Radar · NCT03693989

Clinical Study of the Efficacy of the Ophthalmic Emulsion PRO-145 for Inflammation and Pain After Phacoemulsification

Clinical Study of the Efficacy of the Ophthalmic Emulsion PRO-145 for the Management of Inflammation and Pain After Phacoemulsification Compared to Prednisolone Acetate 1%.

Last checked: Nov 20, 2026Latest source record: Dec 2, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 178 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

178

Actual

Start

Oct 4, 2018

Primary completion

Aug 7, 2019

Study completion Oct 22, 2019

Sponsor

Sponsor type
Industry
First posted
Oct 3, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

objective: To evaluate the efficacy of the ophthalmic emulsion PRO-145 in the treatment of inflammation and pain after phacoemulsification. Hypothesis: The use of the ophthalmic emulsion PRO-145 is effective in decreasing the inflammatory response evaluated by means of cellularity in the anterior chamber, after phacoemulsification. Methodology: Phase III clinical trial, double-blind, controlled, parallel group, multicentre, randomized. Number of patients: 178 subjects divided into 2 groups (89 subjects per group), who will provide an eye for the evaluation of efficacy. Diagnosis and main inclusion criteria: Diagnosis: Postoperative phacoemulsification and foldable intraocular lens placement in a bag.

Conditions

  • Cataract

Interventions

  • Difluprednate 0.05%Drug

    Dosage: 1 drop 4 times a day (every 4 hours) during the period of vigil in the operated eye, for 14 days. Dose reduction for 14 days at the discretion of the principal investigator.

  • PrednefrinDrug

    1 drop 4 times a day (every 4 hours) during the period of vigil in the operated eye, for 14 days. Dose reduction for 14 days at the discretion of the principal investigator. \- Route of administration: topical ophthalmic

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Visual Ability (VA)Time frame: day 28 at the final visit
  2. Adverse EventsTime frame: day 28 at the final visit

Locations

5 sites in 1 country. Site status is shown where the registry gives one.

  • Hospital de la luz

    Mexico City, Mexico

  • Fundación de asistencia privada Conde de Valenciana

    Mexico City, Mexico

  • Catarata y Glaucoma de Occidente

    Guadalajara, Jalisco, Mexico

  • Novam y Vita

    Guadalajara, Jalisco, Mexico

  • Vision Cirugia Ambulatoria

    Monterrey, Nuevo León, Mexico

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.